Nurse Practitioner Program year 2025 Source: CMS Open Payments, 2026 publication

Audrey Soboczynski

Nurse Practitioner West Long Branch, NJ Nurse Practitioner

NPI 1730950676 CMS profile 11568423

842 Broadway, West Long Branch, NJ 07764

Open in the dashboard

General payments

$4,244

247 records reported · program year 2025

Research payments

$0

Paid to them · None reported · program year 2025

Ownership & investment interest

$0

None reported

Through program year 2025, Audrey Soboczynski of West Long Branch, NJ is reported in the CMS Open Payments database as having received $4,244 across 247 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 91st percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

1 row
Year Kind Relative to this record's peak year Amount Records
2025 General $4,244 247

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Audrey Soboczynski
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Audrey Soboczynski were reported at $4,244. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Audrey Soboczynski Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $0 $135 $40–$426 $132
2022 $0 $152 $48–$470 $149
2023 $0 $166 $54–$529 $160
2024 $0 $173 $55–$556 $164
2025 $4,244 $174 $55–$557 $169

Breakdown

Who paid General payments · program year 2025
  1. Janssen Biotech, Inc. $957 44 payments
  2. AbbVie, Inc. $820 57 payments
  3. AstraZeneca Pharmaceuticals LP $783 43 payments
  4. Amgen Inc. $747 35 payments
  5. E.R. Squibb & Sons, L.L.C. $193 20 payments
  6. Novartis Pharmaceuticals Corporation $187 10 payments
  7. Aurinia Pharma U.S., Inc. $168 14 payments
  8. Pfizer Inc. $140 9 payments
  9. Organon LLC $51 3 payments
  10. GlaxoSmithKline, LLC. $47 3 payments
  11. Other $152 9 payments

Every payment, record by record

What the payments were for General payments · program year 2025
  1. Food and Beverage $4,099 245 payments
  2. Education $145 2 payments
Products named General payments · program year 2025
  1. TREMFYA $892 40 payments
  2. SAPHNELO $747 41 payments
  3. SIMPONI ARIA $517 17 payments
  4. KRYSTEXXA $427 21 payments
  5. RINVOQ $424 26 payments
  6. SKYRIZI $396 31 payments
  7. ORENCIA $193 20 payments
  8. COSENTYX $187 10 payments
  9. LUPKYNIS $168 14 payments
  10. XELJANZ $140 9 payments
  11. Other $443 28 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

247 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in New Jersey

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record